Dynein is a large, multi-subunit motor protein complex that generates force along microtubules toward the minus end (retrograde direction), enabling intracellular transport essential for neuronal viability. First characterized in the 1970s as the retrograde motor for axonal transport, dynein has emerged as a critical player in neurodegenerative disease pathogenesis. The dynein family includes cytoplasmic dynein (involved in intracellular transport), axonemal dynein (driving ciliary and flagellar motion), and cytoplasmic dynein-2 (mediating intraflagellar transport). This page focuses on cytoplasmic dynein-1, the primary motor for retrograde axonal transport in neurons.
The significance of dynein in neurodegeneration cannot be overstated. Axonal transport deficits are among the earliest events in many neurodegenerative disorders, and dynein dysfunction sits at the heart of these transport impairments. Understanding dynein biology provides critical insights into disease mechanisms and therapeutic opportunities [1][2].
Cytoplasmic dynein-1 is a massive (~1.5 MDa) protein complex composed of multiple subunits organized into distinct functional domains:
Heavy Chains (DYNC1H1): Two heavy chains (~500 kDa each) form the motor core. Each heavy chain contains:
Intermediate Chains (DYNC1I1, DYNC1I2): Two intermediate chains (~74 kDa each) serve as cargo-binding platforms and link the heavy chains to the dynactin complex. They contain multiple WD-repeat domains that form a β-propeller structure.
Light Intermediate Chains (DYNC1LI1, DYNC1LI2): ~50-55 kDa proteins that further contribute to cargo specificity, particularly for membrane organelles.
Light Chains (DYNLL1, DYNLL2, DYNLRB1, DYNLRB2): The smallest subunits (~8-10 kDa) that stabilize the complex and participate in cargo binding. DYNLL1 (LC8) and DYNLL2 (LC8b) are highly conserved and form homodimers that interact with various cargo proteins, including huntingtin [3].
Dynactin is a critical cofactor that enhances dynein processivity and cargo binding:
Structure: Dynactin is a ~1.1 MDa complex containing over 20 subunits, with p150Glued (DCTN1) being the largest subunit. The complex forms a distinctive shoulder-arm-shaft structure visualized by electron microscopy.
p150Glued subunit: Contains a microtubule-binding domain that directly interacts with microtubules, enhancing dynein processivity. The N-terminal CAP-Gly domain binds to microtubules, while the central coiled-coil mediates interaction with dynein intermediate chains.
Arp1 filament: A short actin-like filament that serves as a scaffold for other dynactin subunits and connects to the dynein-dynactin complex.
The dynein-dynactin interaction is essential for most cellular functions, and disruption of this interaction is implicated in multiple neurodegenerative diseases [1:1][4].
Dynein generates force through a coordinated ATPase cycle coupled to conformational changes:
Unlike kinesin, which moves processively toward microtubule plus ends, dynein exhibits a more variable stepping pattern and can move bidirectionally under certain conditions, though with a net retrograde bias.
The dynactin complex dramatically enhances dynein processivity (the number of steps taken before detachment) from ~1-2 steps to >10 steps. This enhancement involves:
This processivity enhancement is critical for long-distance transport in axons, which can extend over a meter in human neurons [5][6].
Dynein powers retrograde transport from the distal axon toward the cell body, moving diverse cargoes essential for neuronal health:
Cargo types:
Physiological significance:
The continuous operation of dynein-mediated transport is essential for axon maintenance, as disruption leads to accumulation of organelles and proteins at distal sites, impaired signaling, and ultimately axonal degeneration [2:1][7].
Dynein plays critical roles in synapse assembly, function, and plasticity:
Presynaptic function:
Postsynaptic function:
Synaptic plasticity:
The bidirectional nature of dynein transport, modulated by various regulatory proteins, allows dynamic regulation of synaptic composition and function [8].
Beyond long-distance transport, dynein participates in organelle positioning:
Lysosome positioning: Dynein positions lysosomes at perinuclear locations in cell bodies, while local lysosome distribution in axons is regulated by dynein activity.
Mitochondrial distribution: While kinesins primarily drive mitochondrial long-distance transport, dynein participates in their retrograde movement and positioning.
Endosome trafficking: Dynein mediates movement of early endosomes, recycling endosomes, and late endosomes, coordinating cargo delivery and signaling.
The precise positioning of organelles is essential for neuronal function, and dynein dysfunction disrupts these spatial relationships [9].
Dynein dysfunction is among the earliest events in Alzheimer's disease pathogenesis:
Tau pathology effects: Hyperphosphorylated tau dissociates from microtubules, destabilizing the microtubule tracks required for dynein-mediated transport. This leads to:
The relationship between tau and dynein is bidirectional: dynein dysfunction also exacerbates tau pathology by impairing the transport of enzymes that regulate tau phosphorylation [10].
Amyloid-beta effects: Aβ oligomers directly impair dynein function through multiple mechanisms:
Evidence from models:
Amyloid precursor protein (APP) and dynein: The APP intracellular domain interacts with dynein, and this interaction may be relevant to APP trafficking and processing [11].
Dynein contributes to several aspects of PD pathogenesis:
LRRK2 interactions: LRRK2 (leucine-rich repeat kinase 2) mutations are a common cause of familial PD. LRRK2 phosphorylates several components of the dynein complex, including DYNC1I1, regulating transport efficiency. PD-associated LRRK2 mutations alter this phosphorylation, impairing dynein function.
Alpha-synuclein effects: Lewy bodies (α-syn aggregates) disrupt dynein-mediated transport in multiple ways:
PINK1-Parkin-mitophagy pathway: While mitophagy primarily involves kinesin-1 for autophagosome retrograde transport, dynein may participate in later stages of autophagosome-lysosome fusion and may regulate the initiation of mitophagy.
Evidence: Studies in PD models show dynein-dependent transport deficits, and dynein dysfunction may contribute to the characteristic pattern of axonal degeneration in PD [12].
Dynein plays a particularly central role in Huntington's disease pathogenesis:
Huntingtin-dynein interaction: The huntingtin protein (HTT) directly interacts with dynein intermediate chains through its HAP40 (Huntingtin-associated protein 40) subunit. This interaction is essential for normal retrograde transport.
Mutant huntingtin effects:
BDNF transport deficit: BDNF (Brain-Derived Neurotrophic Factor) signaling is essential for striatal neuron survival. Dynein-mediated BDNF vesicle transport is impaired in HD, contributing to the characteristic degeneration of striatal neurons.
Evidence: Multiple studies demonstrate dynein-dependent transport deficits in HD models, and restoring dynein function has shown therapeutic promise in preclinical studies [@engleender2005][3:1][13].
Dynein dysfunction is a key component of ALS pathogenesis:
DYN1CH mutations: Dominant mutations in DYNC1H1 cause familial ALS with predominantly lower motor neuron involvement. These mutations impair dynein function through various mechanisms:
Dynactin mutations: DCTN1 (p150Glued) mutations cause ALS-FTD (frontotemporal dementia). These mutations disrupt the dynein-dynactin complex, impairing retrograde transport.
Disrupted cargo transport:
TDP-43 pathology: TDP-43 aggregates (the hallmark of most ALS cases) disrupt dynein function through multiple mechanisms, creating a feed-forward loop of dysfunction.
Evidence: Dynein function is impaired in ALS patient tissue and models, and dynein-enhancing strategies have shown promise in preclinical studies [14].
Dynein dysfunction triggers a cascade of cellular deficits:
This cascade explains why dynein dysfunction is such a critical event in neurodegeneration [6:1][15].
Dynein activators: Compounds that enhance dynein ATPase activity or processivity are being explored. However, the challenge lies in achieving specificity for neurons without disrupting other dynein functions.
Microtubule stabilizers: Taxol and related compounds stabilize microtubules, indirectly enhancing dynein function by providing better tracks. However, these approaches face challenges in achieving sufficient brain penetration and avoiding toxicity.
Dynactin stabilizers: Compounds that enhance the dynein-dynactin interaction may improve transport efficiency. The p150Glued subunit is a particular target.
Gene therapy:
Antisense oligonucleotides: ASOs targeting DYNC1H1 or DCTN1 for downregulation in specific disease contexts (e.g., reducing dynein function in ALS to slow axonal transport of SOD1 aggregates).
| Disease | Target | Approach |
|---|---|---|
| AD | Microtubule stabilization | Tau reduction, microtubule stabilizers |
| PD | LRRK2-dynein interaction | LRRK2 inhibitors, downstream modulation |
| HD | Huntingtin-dynein | HTT lowering, dynein modulators |
| ALS | DYNC1H1/DCTN1 | Gene therapy, ASOs |
The dynein field continues to advance rapidly, with multiple therapeutic candidates in various stages of development. Understanding the precise mechanisms of dynein dysfunction in each disease will be essential for developing effective treatments [16].
Axonal transport is an attractive therapeutic target because:
Dynein-mediated retrograde axonal transport is essential for neuronal health, and its dysfunction plays a central role in multiple neurodegenerative diseases. The molecular understanding of dynein has advanced dramatically, revealing:
As the field advances, dynein-based therapies may provide meaningful benefit for patients with AD, PD, HD, ALS, and other neurodegenerative disorders.
Karki S, Holzbaur EL. Cytoplasmic dynein and dynactin in intracellular motility. Curr Opin Cell Biol. 1999. ↩︎ ↩︎
Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science. 1998. ↩︎ ↩︎
Gauthier LR, et al. Dynein light chain binding to mutant huntingtin aggregates. J Neurosci. 2004. ↩︎ ↩︎
Reed NA, et al. Microtubule-based transport in neurons: the goods and the bad. Curr Biol. 2006. ↩︎
Vallee RB, et al. Dynein and its many functions. Methods Cell Biol. 2001. ↩︎
Lenz ML, et al. Dynein as a modulator of neurodegeneration. Cell. 2006. ↩︎ ↩︎
Chevalier-Larsen E, Holzbaur EL. Axonal transport and neurodegenerative disease. Biochim Biophys Acta. 2006. ↩︎
Ayloo S, et al. Dynein-mediated transport during synapse function and dysfunction. Curr Opin Neurobiol. 2014. ↩︎
Ligon LA, et al. Dynein and lysosome trafficking in neurons. Traffic. 2005. ↩︎
Song MS, et al. Dynein and tau: pathogenic interactions in Alzheimer's disease. Trends Neurosci. 2005. ↩︎
Stokin GB, et al. Axonal transport deficits in early Alzheimer's disease. Science. 2005. ↩︎
Zhao J, et al. Dynein dysfunction and alpha-synuclein pathology in Parkinson's disease. Brain. 2024. ↩︎
Mitchell JC, et al. Dynein and the pathogenesis of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2012. ↩︎
Chen X, et al. Dynein-dynactin complex disruption in ALS. Neuron. 2021. ↩︎
Schiavo G, et al. Retrograde axonal transport machinery in neurodegeneration. Trends Neurosci. 2020. ↩︎
Encarnacao M, et al. Targeting dynein as a therapeutic strategy in neurodegenerative disease. Nat Rev Drug Discov. 2023. ↩︎